A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Tumors Lymphomas

Interventions

BIOLOGICAL: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.